The safety profile and efficacy of the KISIMA-Mash2 vaccine in the Apc+/Min-FCCC mouse supports the use of the KISIMA platform, as well as the human Ascl2 antigen as a molecular target, for preventive intervention in populations at elevated risk for CRC. This evidence concerns the gene ASCL2 and colorectal carcinoma.